Post-Approval Drug Safety Strategies - Dear Colleague

Dear Colleague:

I am pleased to announce the production of the Pharmaceutical Strategy Series’ Third annual executive forum “Post-Approval Drug Safety Strategies: Best Practices to Assess and Mitigate Risks throughout the Product’s Life Cycle” being held November 12-14, 2008 at The Ritz-Carlton, Pentagon City in Arlington, VA.

Improving products’ effective clinical safety will increase the industry’s fundamental value proposition to patients, healthcare providers, payors and regulators. The program will focus on pharmacovigilance program implementation and specific strategies and approaches to creating true value from a peri- and post-approval drug safety program. Drug safety programs and monitoring and the approach of this conference are not to look at safety in the silos of early-phase safety or post-approval safety but to view safety holistically, across the lifecycle, especially at the transition from approval to broader use in the marketplace.

The special, three-day executive forum entitled “Post-Approval Drug Safety Strategies: Best Practices to Assess and Mitigate Risks throughout the Product’s Life Cycle” will tackle many of the pressing issues that executives are facing today.

Topics Include:

The Pharmaceutical Strategy Series’ ( PSS ) mission is to assist in improving the overall health of the pharmaceutical industry by producing high-level meetings that bring together R&D leaders to discuss and debate potential solutions to overcoming the most pressing challenges facing their organizations. I hope you can join us on November 12-14, 2008 in Arlington, VA to discuss and debate this emerging drug safety paradigm and how innovative drug safety risk assessment, management and mitigation hold the promise of creating considerable value for the industry.

Very sincerely,

Micah Lieberman